Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.67 |
| ▸ | MGLL | Q99685 | 5/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.56 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27957268 | 0.85 | HSD11B1 (0.61) | HSD11B1MGLLEPHX2KDM2BPOLB | |
| SCHEMBL14637673 | 0.84 | HSD11B1 (0.73) | HSD11B1MGLLEPHX2KDM2BPOLB | |
| SCHEMBL6140623 | 0.81 | HSD11B1 (0.66) | HSD11B1MGLLEPHX2KDM2BPOLB | |
| SCHEMBL12576441 | 0.80 | HSD11B1 (1.00) | HSD11B1MGLLPOLBALDH1A1LMNA | |
| SCHEMBL4236625 | 0.79 | HSD11B1 (0.65) | HSD11B1MGLLEPHX2KDM2BPOLB | |
| SCHEMBL30534113 | 0.76 | TP53 (0.64) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13873393 | 0.75 | CYP2C9 (0.76) | HSD11B1MGLLEPHX2POLBKMT2A | |
| SCHEMBL9965446 | 0.75 | GAA (0.54) | EPHX2ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27968916 | 0.75 | HSD11B1 (0.60) | HSD11B1MGLLEPHX2KDM2BPOLB | |
| SCHEMBL5472042 | 0.75 | HSD11B1 (0.62) | HSD11B1MGLLPOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | HSD11B1 1/4885MGLL 2824/4885EPHX2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.